CombiMatrix (NASDAQ: CBMX) provides clinical molecular diagnostic laboratory services in the United States. The company focuses on pre-implantation genetic screening, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders. It provides molecular diagnostic services primarily in the areas of reproductive health for the diagnosis of developmental disorders associated with intellectual disability, congenital anomalies, dysmorphic features, and autism spectrum disorders. The company’s testing focuses on advanced technologies, including single nucleotide polymorphism, chromosomal microarray analysis, sequencing, fluorescent in situ hybridization, and high resolution karyotyping. For more information, visit the company’s website at www.combimatrix.com.
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides to users (1) access to our news aggregation and syndication servers, (2) enhanced press release services, and (3) a full array of social communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com